More recent studies underlined the role of EphA2 in driving therapy-resistant pancreatic adenocarcinomas, suggesting that EphA2-targeting agents should be developed and used in combination with current therapeutics [26]. This evidence concerns the gene EPHA2 and pancreatic adenocarcinoma.